Search

T-5224

T-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.

SNS-032

Brilaroxazine

Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. … /ADHD), and autism.

Influenza A virus A/Victoria/361/2011 (H3N2) recombinant hemagglutinin antigen

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.

Influenza B virus B/Wisconsin/1/2010 recombinant hemagglutinin antigen

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.

Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (propiolactone inactivated)

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.

Influenza A virus A/Christchurch/16/2010 NIB-74 (H1N1) antigen (propiolactone inactivated)

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.

Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) antigen (propiolactone inactivated)

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.

Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (formaldehyde inactivated)

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.